Skip to main content

Breast Cancer Translational Research Laboratory J.C. Heuson

Description

The aim of the Institut Bordet J.-C. Heuson Breast Cancer Translational Research Laboratory (BCTL) is to facilitate the transfer of scientific discoveries about breast cancer that are made in the laboratory into clinical practice. It seeks to improve the molecular characterisation of breast cancer through the use of leading-edge technologies. A particular objective is to improve understanding of the biology of these cancers and of the mechanisms involved in resistance to treatment.

Research Projects

The various projects of the laboratory are funded by : The Association Jules Bordet, FNRS, FNRS-Télévie, Fondation contre le Cancer, Breast Cancer Research Fondation (BCRF), Fonds Julie et Françoise Drion.

Project 1

MOLECULAR CHARACTERIZATION OF BREAST CANCER HETEROGENEITY USING SPATIAL TRANSCRIPTOMICS AND SINGLE CELL ANALYSIS
  • Project leader(s) : Christos Sotiriou, Françoise Rothé
  • Collaborations : 
    • Prof. Lundeberg at the SciLife laboratory (Stockholm, Sweden)
    • Dr Frédérick Libert, ULB/VUB Brightcore sequencing facility

Projet 2

Mapping triple negative breast cancer heterogeneity by leveraging spatial transcriptomics and artificiaL intelligence: towards an optimized patients’ care
  • Project leader(s) : Christos SotiriouFrançoise RothéDavid Venet, Nicola Occelli

Projet 3

DISSECTING THE IMPACT OF INTRATUMOR HETEROGENEITY ON DISEASE RELAPSE IN LUMINAL BREAST CANCER IN THE CONTEXT OF THE MINDACT CLINICAL TRIAL
  • Project leader(s) : Christos SotiriouFrançoise RothéLaetitia Collet
  • Collaborations : Prof. Christine Desmedt, Marion Maetens, PhD (KU Leuven)

Projet 4

UNCOVERING THE IMMUNE LANDSCAPE OF BREAST CANCER 
  • Project leader(s) : Christos SotiriouLaurence Buisseret, Françoise Rothé
  • Collaborations : Prof John Stagg CR-CHUM, Montreal, Canada

Projet 5

MOLECULAR CHARACTERIZATION OF INTRATUMOR HETEROGENEITY AND TUMOR MICROENVIRONMENT IN HIGH GRADE SEROUS OVARIAN CANCER AND BRCA1/2 MUTANT BREAST CANCER USING SPATIAL TRANSCRIPTOMICS
  • Project leader(s) : Christos SotiriouFrançoise Rothé
  • Collaborations : Prof Isabelle Ray-Coquard (Centre Léon Bérard, Lyon)

Our team

Head of BCTL
Prof Christos Sotiriou, MD PhD

Team
Françoise Rothé, PhD, Doctor of Sciences
Laurence Buisseret, Clinical scientist (MD, PhD)
David Venet, PhD, Post-Doc Bioinformatics
Danai Fimereli, PhD, Post-Doc Bioinformatics
David Gacquer, PhD, Post-Doc Bioinformatics
Mattia Rediti, PhD Student (MD)
Xiao Xiao Wang, PhD Student (MD)
Laetitia Collet, PhD Student (MD)
Jérémy Blanc, PhD Student (MD)
Elisa Agostinetto, PhD Student (MD)
Andrea Joaquin Garcia, PhD Student (Bioinformatics)
Matteo Serra, PhD Student (Bioinformatics)
Nicola Occelli, PhD Student (Bioinformatics)
Andreas Papagiannis, PhD Student (Bioinformatics)
Maria Alexandra Stanciu, PhD Student (Bioinformatics)
Lucie Cervenkova, PhD Student (Bioinformatics)
Bengisu Karakose, PhD Student (Bionformatics)
Zoë Denis, MSc (Junior Scientist)
Marcela Carausu, ESMO Fellow (MD)
Samira Majjaj, Technician
Ghizlane Rouas, Technician
Delphine Vincent, Technician

Administrative assistant
Anastasia Iordanidou

04/12/2023

 Scientific publications

Reply to S. Di Cosimo et al.

Authors : Agostinetto E, Venet D, Ignatiadis M, Kalashnikova E
Year : 2023
Journal : JCO Precis Oncol
Volume : 7
Pages : e2200644

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges.

Authors : Wang X, Collet L, Rediti M, Debien V, De Caluwé A, Venet D, Romano E, Rothé F, Sotiriou C, Buisseret L
Year : 2023
Journal : J Clin Med
Volume : 12

Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D).

Authors : Pondé N, Agbor-Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C, Werner O, Gelber Rd, Jatoi A, Dueck AC, Moreno-Aspitia A, Sotiriou C, de Azambuja E, Piccart M
Year : 2022
Journal : Breast Cancer Res Treat
Volume : 191
Pages : 225

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.

Authors : Chang CA, Jen J, Jiang S, Sayad A, Mer AS, Brown KR, Nixon AML, Dhabaria A, Tang KH, Venet D, Sotiriou C, Deng J, Wong KK, Adams S, Meyn P, Heguy A, Skok JA, Tsirigos A, Ueberheide B, Moffat J, Singh A, Haibe-Kains B, Khodadadi-Jamayran A, Neel BG
Year : 2022
Journal : Cancer Discov
Volume : 12
Pages : 1022-1045

Incorporation of TILs in daily breast cancer care: how much evidence can we bear?

Authors : Lænkholm AV, Callagy G, Balancin M, Bartlett JMS, Sotiriou C, Marchio C, Kok M, Dos Anjos CH, Salgado R
Year : 2022
Journal : Virchows Arch
Volume : 480
Pages : 147-162